Humanigen — Investor Presentation (April 2022)
18 slides from Humanigen's investor presentation, Apr 12, 2022
Slide 1: Executive Overview April 2022
Executive Overview April 2022 Humanigen, Inc.
Slide 2: Cautionary Note Regarding Forward-Looking Statements
2 Lenzilumab is being developed as a potential treatment for COVID - 19; it is not currently approved or authorized for use in any c ountry Cautionary Note Regarding Forward - Looking Statements All statements other than statements of historical facts contained in this presentation are forward - loo
Slide 3: Lenzilumab COVID Multinational Clinical Pipeline
3 Lenzilumab is being developed as a potential treatment for COVID - 19; it is not currently approved or authorized for use in any c ountry Lenzilumab COVID Multinational Clinical Pipeline S t ud y N a m e Phase Status Centers Partners LIVE - AIR 3 Completed 520 patients REGISTRATIONAL 24 US 11 Braz
Slide 4: Non COVID Clinical Pipeline: Trials with Multinational Reach
4 Lenzilumab is being developed as a potential treatment for COVID - 19; it is not currently approved or authorized for use in any c ountry Non COVID Clinical Pipeline: 4 Trials with Multinational Reach Study Name a n d I nd i ca ti o n Phase Status Centers Partners Lenzilumab SHIELD P r o p h y l a
Slide 5: Key COVID-19 U.S. Statistics
5 Lenzilumab is being developed as a potential treatment for COVID - 19; it is not currently approved or authorized for use in any c ountry Key COVID - 19 U.S. Statistics Delta Omicron Alpha 1 https://covid.cdc.gov/covid - data - tracker/#new - hospital - admissions (Accessed April 7, 2022 ) 2 https
Slide 6: Flu Provides Example of Endemic Market
6 Lenzilumab is being developed as a potential treatment for COVID - 19; it is not currently approved or authorized for use in any c ountry Flu Provides Example of Endemic Market COVID - 19 has many similarities to other viruses that have been around for decades, but also several key differences (e.
Slide 7: Humanigen and LENZ
7 Lenzilumab is being developed as a potential treatment for COVID - 19; it is not currently approved or authorized for use in any c ountry Humanigen and LENZ® ▪ LENZ (lenzilumab) is a variant - agnostic immunomodulatory antibody discovered, developed and to be commercialized by Humanigen ▪ We belie
Slide 8: Recent COVID/LENZ Updates
8 Lenzilumab is being developed as a potential treatment for COVID - 19; it is not currently approved or authorized for use in any c ountry ACTIV - 5/BET - B Topline data 2Q22 C - SMART Lenzilumab shipped to Australia Korean PK study Lenzilumab shipped to Korea SHIELD Protocol with FDA, first patien
Slide 9: The Lancet Respiratory Medicine: Peer-Reviewed LIVE-AIR Phase 3 Publication
9 Lenzilumab is being developed as a potential treatment for COVID - 19; it is not currently approved or authorized for use in any c ountry The Lancet Respiratory Medicine: Peer - Reviewed LIVE - AIR Phase 3 Publication LIVE - AIR showed that lenzilumab treatment of hospitalised patients with COVID
Slide 10: Target Patient Segment: CRP<150mg/L, Age <85
10 Lenzilumab is being developed as a potential treatment for COVID - 19; it is not currently approved or authorized for use in any c ountry Target Patient Segment: CRP<150mg/L, Age <85 Patients Who Died Or Required IMV Kaplan─Meier Estimate a 15.6 8.4 9.2 22.1 21.2 24.8 0% 5% 10% 15% 20% 25% 30% Ov
Slide 11: Economic Benefits in Target Patient Population
11 Lenzilumab is being developed as a potential treatment for COVID - 19; it is not currently approved or authorized for use in any c ountry Economic Benefits in Target Patient Population Clinical Benefits Translate to a Cost Savings $11,858 per patient with or without remdesivir 2 Bed Days Saved 0
Slide 12: Estimated Clinical Benefits of Lenzilumab and Standard of Care
12 Lenzilumab is being developed as a potential treatment for COVID - 19; it is not currently approved or authorized for use in any c ountry Estimated Clinical Benefits of Lenzilumab and Standard Of Care Over Standard of Care Alone CRP, C - reactive protein; ICU, intensive care unit; IMV, invasive m
Slide 13: Current U.S. COVID Treatments Highlight Unmet Need And Opportunity
13 Lenzilumab is being developed as a potential treatment for COVID - 19; it is not currently approved or authorized for use in any c ountry Current U.S. COVID - 19 Treatments Highlight Unmet Need And Opportunity For Lenzilumab In Hospital Hyperinflammatory Phase Pulmonary/Inflammatory Phase Early I
Slide 14: SHIELD Phase 3 Study of Lenzilumab with Yescarta and Tecartus
14 Lenzilumab is being developed as a potential treatment for COVID - 19; it is not currently approved or authorized for use in any c ountry SHIELD Phase 3 Study of Lenzilumab with Yescarta (Axi - Cel) and Tecartus (Brexu - Cel) ▪ FDA registration pathway for Phase 3 clinical development of lenzilum
Slide 15: RATinG Study: Addressing High Unmet Need in aGvHD
15 Lenzilumab is being developed as a potential treatment for COVID - 19; it is not currently approved or authorized for use in any c ountry ▪ 22 sites selected ▪ UK regulatory submission completed ▪ First patient to be dosed 2Q22 RATinG Study: Addressing High Unmet Need in aGvHD To be conducted in
Slide 16: PREACH-M Trial Phase 2/3 for CMML
16 Lenzilumab is being developed as a potential treatment for COVID - 19; it is not currently approved or authorized for use in any c ountry PREACH – M Trial Phase 2/3 for CMML: Recruitment Commenced October 2021 1. Murthy et al, Leukemia Lymphoma, 2017 Jul;58(7):1648 - 1654 2. SEER Hematopoietic an
Slide 17: Initial 2022 Goals
17 Lenzilumab is being developed as a potential treatment for COVID - 19; it is not currently approved or authorized for use in any c ountry Initial 2022 Goals COVID PK study in Korean patients RATinG Phase 2/3 aGvHD study C - SMART COVID in cancer patients Clinical Topline results from ACTIV - 5/BE
Slide 18: Thank You For Your Attention
Thank You For Your Attentio n VISIT OUR SIT E